The EPS beat is overshadowed by the revenue collapse and widening net loss. The key catalyst is the SUPRAME Phase 3 data trigger in 2026, a positive readout would validate the commercial thesis and could drive a 50%+ move. Monitor ASCO 2026 presentations for IMA203CD8 and IMA402 data as near-term sentiment drivers. The $521.5M cash runway into 2028 provides a long execution window, reducing near-term financing risk.
IMTX drugs
IMTX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 12 $11.39entry
- T+1 · 6mo ago −5.27%α −5.84% · $10.79
- T+5 · 6mo ago −6.76%α −6.84% · $10.62
- T+20 · 5mo ago −22.12%α −20.40% · $8.87
- T+60 · 3mo ago −17.30%α −21.68% · $9.42
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Immatics reported Q1 2026 EPS of -$0.29, a 33.9% beat vs consensus of -$0.44, but revenue fell sharply to $8.7M from $21.4M YoY due to lower collaboration cost recognition. The net loss widened to $66.5M from a prior-year net profit of $45.9M, driven by higher R&D spending on the SUPRAME Phase 3 trial and early commercial preparations. The stock's move will hinge on the upcoming SUPRAME interim/final analysis triggers in 2026 and multiple ASCO data readouts, not the mixed quarterly financials.
Key Financial Metrics
Key Facts
- EPS of -$0.29 beat consensus of -$0.44 by 33.9%
- Revenue of $8.7M declined 59.3% YoY from $21.4M due to lower collaboration cost recognition
- Net loss of $66.5M vs net profit of $45.9M in Q1 2025
- Cash and financial assets of $521.5M as of March 31, 2026, with cash reach projected into 2028
- SUPRAME Phase 3 interim and final analyses expected to be triggered in 2026
- BLA submission expected in H1 2027 with commercial launch in H2 2027
- Multiple ASCO 2026 data readouts across PRAME cell therapy and bispecific programs
- R&D expenses rose 41.3% YoY to $68.1M driven by SUPRAME trial costs
- Completed at-the-market offering of $24.4M net proceeds in Q1 2026
Financial Impact
Revenue decline of $12.7M YoY and net loss swing of $112.4M from profit to loss; cash burn of ~$42M in operating cash flow for the quarter
Risk Factors
- SUPRAME Phase 3 trial may fail to meet PFS or OS endpoints, destroying the commercial thesis
- Revenue is lumpy and dependent on collaboration milestones, not recurring
- Net loss is widening rapidly with R&D spend increasing 41% YoY
- Dilution risk from at-the-market offering program
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292675 |
Track record
23 reports on IMTX
8 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 5/10 No price data
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
- Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
- Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
- Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers